5.1 Own Publications

[1] Zeng Y; Fest S; Kunert R; Katinger H; Pistoia V; Michon J; Lewis G; Ladenstein R; Lode HN.: Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice. Mol Immunol. 2005 Jul;42(11) , 1311-9.

[2]. Huebener,N.; Lange,B.; Lemmel,C.; Rammensee,H.G.; Strandsby,A.; Wenkel,J.; Jikai,J.; Zeng,Y.; Gaedicke,G.; Lode,H.N.: Vaccination with minigenes encoding for novel 'self' antigens are effective in DNA-vaccination against neuroblastoma. Cancer Lett. 2003 ; Jul 18;197(1-2) , 211-7.

[3]. Lode,H.N.; Huebener,N.; Zeng,Y.; Fest,S.; Weixler,S.; Gaedicke,G.: DNA minigene vaccination for adjuvant neuroblastoma therapy. Ann N Y Acad Sci. 2004 Dec;1028, 113-21.

[4]. Zeng Y; Jiang J ; Huebener N ; Wenkel J ; Gaedicke G ; Xi a ng R ; Lode HN. Fractalkine gene therapy for neuroblastoma is more effective in combination with targeted IL-2. Cancer Lett. 2005 Jun 10.

5.2 Publications of other authors

(1) Lode HN, Pertl U, Xiang R, Gaedicke G, Reisfeld RA.: Tyrosine hydroxylase-based DNA-vaccination is effective against murine neuroblastoma. Med Pediatr Oncol. 2000 , 35(6), 641-646.

(2) Pan Y, Lloyd C, Zhou H, Dolich S, Deeds J, Gonzalo JA et al.: Neurotactin a membrane-anchored chemokine upregulated in brain inflammation. Nature. 1997 ; 387(6633), 611-617.

(3) Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D et al.: A new class of membrane-bound chemokine with a CX3C motif. Nature. 1997 ; 385(6617), 640-644.

(4) Umehara H, Bloom ET, Okazaki T, Nagano Y, Yoshie O, Imai T.: Fractalkine in vascular biology: from basic research to clinical disease. Arterioscler Thromb Vasc Biol. 2004 , 24(1), 34-40.

(5) Garton KJ, Gough PJ, Blobel CP, Murphy G, Greaves DR, Dempsey PJ et al.: Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem. 2001 ; 276(41), 37993-38001.

(6) Moser B, Loetscher P.: Lymphocyte traffic control by chemokines, Nat Immunol. 2001 , 2(2), 123-128.

(7) Fong AM, Robinson LA, Steeber DA, Tedder TF, Yoshie O, Imai T et al.: Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med. 1998 , 188(8), 1413-1419.

(8) Haskell CA, Cleary MD, Charo IF.: Molecular uncoupling of fractalkine-mediated cell adhesion and signal transduction. Rapid flow arrest of CX3CR1-expressing cells is independent of G-protein activation. J Biol Chem. 1999 , 274(15), 10053-10058.

(9) Moatti D, Faure S, Fumeron F, Amara M, Seknadji P, McDermott DH et al.: Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood. 2001 , 97(7), 1925-1928.

(10) Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M et al.: Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell. 1997 , 91(4), 521-530.

(11) Nishimura M, Umehara H, Nakayama T, Yoneda O, Hieshima K, Kakizaki M et al.: Dual functions of fractalkine/CX3C ligand 1 in trafficking of perforin+/granzyme B+ cytotoxic effector lymphocytes that are defined by CX3CR1 expression. J Immunol 2002; 168(1) , 6173-6180.

(12) Fraticelli P, Sironi M, Bianchi G, D'Ambrosio D, Albanesi C, Stoppacciaro A et al.: Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest 2001; 107(9), 1173-1181.

(13) Yoneda O, Imai T, Nishimura M, Miyaji M, Mimori T, Okazaki T et al.: Membrane-bound form of fractalkine induces IFN-gamma production by NK cells. Eur J Immunol 2003, 33(1), 53-58.

(14) Nanki T, Imai T, Nagasaka K, Urasaki Y, Nonomura Y, Taniguchi K et al.: Migration of CX3CR1-positive T cells producing type 1 cytokines and cytotoxic molecules into the synovium of patients with rheumatoid arthritis. Arthritis Rheum 2002, 46(11), 2878-2883.

(15) Borrello I, Pardoll D.: GM-CSF-based cellular vaccines: a review of the clinical experience. Cytokine Growth Factor Rev 2002, 13(2), 185-193.

(16) Lode HN, Xiang R, Duncan SR, Theofilopoulos AN, Gillies SD.: Reisfeld RA. Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12. Proc Natl Acad Sci U S A 1999, 96(15) , 8591-8596.

(17) Becker JC, Pancook JD, Gillies SD, Furukawa K.: Reisfeld RA. T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J Exp Med 1996, 183(5), 2361-2366.

(18) Xiang R, Lode HN, Gillies SD., Reisfeld RA.: T cell memory against colon carcinoma is long-lived in the absence of antigen. J Immunol 1999, 163(7), 3676-3683.

(19) Eklund JW, Kuzel TM. A review of recent findings involving interleukin-2-based cancer therapy. Curr Opin Oncol 2004 ; 16(6), 542-546.

(20) Lode HN, Xiang R, Dreier T, Varki NM, Gillies SD, Reisfeld RA. Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy . Blood 1998 ; 91(5), 1706-1715.

(21) Audibert FM, Lise LD. Adjuvants: current status, clinical perspectives and future prospects. Immunol Today 1993 ; 14(6), 281-284.

(22) Allison AC, Byars NE. Immunological adjuvants: desirable properties and side-effects. Mol Immunol 1991 ; 28(3), 279-284.

(23) Takahashi H, Takeshita T, Morein B, Putney S, Germain RN, Berzofsky JA. Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs. Nature 1990 ; 344(6269),873-875.

(24) Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998 ; 4(3), 321-327.

(25) Xin H, Kikuchi T, Andarini S, Ohkouchi S, Suzuki T, Nukiwa T et al. Antitumor immune response by CX3CL1 fractalkine gene transfer depends on both NK and T cells. Eur J Immunol 2005 ; 35(5),1 371-1380.

(26) Lode HN, Xiang R, Varki NM, Dolman CS, Gillies SD, Reisfeld RA. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. J Natl Cancer Inst 1997 ; 89(21),1586-1594.

(27) Becker JC, Pancook JD, Gillies SD, Furukawa K, Reisfeld RA. T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J Exp Med 1996 ; 183(5) , 2361-2366.

(28) Xiang R, Lode HN, Dolman CS, Dreier T, Varki NM, Qian X et al. Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy. Cancer Res 1997 ; 57(21), 4948-4955.

(29) Xiang R, Lode HN, Gillies SD, Reisfeld RA. T cell memory against colon carcinoma is long-lived in the absence of antigen . J Immunol 1999; 163(7 , 3676-3683.

(30) Niethammer D, Handgretinger R.: Clinical strategies for the treatment of neuroblastoma. Eur J Cancer 1995, 31A(4):568-571.

(31) Roth JA, Cristiano RJ.: Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst 1997. 89(1), 21-39.

(32) Becker JC, Varki N, Gillies SD, Furukawa K, Reisfeld RA.: An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response. Proc Natl Acad Sci U S A 1996, 93(15), 7826-7831.

(33) Becker JC, Varki N, Gillies SD, Furukawa K, Reisfeld RA.: Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy. J Clin Invest 1996. 98(12), 2801-2804.

(34) Xiang R, Lode HN, Dreier T, Gillies SD, Reisfeld RA.: Induction of persistent tumor-protective immunity in mice cured of established colon carcinoma metastases. Cancer Res 1998. 58(17), 3918-3925.

© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.
XDiML DTD Version 4.0Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML-Version erstellt am: